September happens to be National Cholesterol Education Month, so it’s a good excuse to talk about something I’ve wanted people to understand for years: your cholesterol number isn’t your cardiovascular destiny.
You know the routine. You get blood drawn. A few days later you open the patient portal and immediately hunt for the little red H’s and L’s.
Total cholesterol: 212.
LDL: 132.
Uh-oh. Or perhaps your LDL is 96 and you breathe a sigh of relief. Not so fast in either direction.
I’m a healthcare practitioner, so of course I care about LDL cholesterol. LDL-C is strongly related to atherosclerotic cardiovascular disease (ASCVD), and lowering LDL in appropriate patients reduces cardiovascular events. I don’t subscribe to the internet theory that LDL doesn’t matter.
LDL matters enormously. And LDL-C is one piece of a much larger cardiovascular puzzle.
In fact, the new 2026 ACC/AHA GUIDELINES on the Management of Dyslipidemia reflects this broader thinking. It replaces the 2018 cholesterol guideline and specifically addresses atherogenic particles beyond LDL-C, including triglyceride-rich remnant particles and lipoprotein(a), or Lp(a). The guideline also brings back LDL-C and non-HDL-C treatment goals and expands the role of coronary artery calcium scoring in selected patients.
So let’s go beyond the basic cholesterol panel.
First, A Little Story
Imagine a woman I’ll call Mona. She’s 58, exercises several times a week, doesn’t smoke and generally eats well, although she’s been known to polish off more ice cream than she intended to. Her annual lipid panel always looks fairly respectable.
LDL-C: 104 mg/dL.
HDL-C: 68.
Triglycerides: 91.
Her doctor isn’t particularly concerned. Mona isn’t either. But her dad had a heart attack at 52 so there’s a family history. That’s the sentence that changes the conversation. So she asks for an Lp(a) test because she read that it’s largely inherited. Hers comes back elevated, no surprise to her.
Suddenly, an LDL of 104 doesn’t look quite as reassuring as it did five minutes ago. It’s not like her LDL chanted, but the context did.
That’s the point of this article.
Risk assessment isn’t about finding one number that looks scary. I’ve always cautioned people not to become a “number junkie” something I first mentioned in my book Diabetes Without Drugs.
Because I care about you, I want to emphasize this part –> it’s about putting the numbers together with other things like your age, blood pressure, blood sugar levels, kidney function, and possibly other biomarkers that you can get off an OATS test. Take all that and consider your smoking history, family’s medical history and any scans or imaging that might be relevant. Then you have a real picture. 
Here are seven other (maybe better!) tests that tell you more:
1. ApoB: How Many Atherogenic Particles Are Actually Circulating?
This is one of my favorite tests because it helps explain something a standard lipid panel can sometimes obscure.
LDL-C tells you approximately how much cholesterol is being carried inside LDL particles.
Apolipoprotein B, or ApoB, gives you information about the number of atherogenic lipoprotein particles circulating in your blood.
Why?
Each major atherogenic particle—LDL, IDL, VLDL remnants and Lp(a)—carries one ApoB molecule.
Think of LDL-C as the amount of cargo and ApoB as a way of counting the cargo-carrying vehicles. Sometimes those measurements are discordant. Someone can have an LDL-C that doesn’t look alarming but still have many cholesterol-carrying particles circulating through the arteries.
This is particularly relevant with diabetes, metabolic syndrome and elevated triglycerides.
The 2026 ACC/AHA guideline says ApoB can be useful for improving risk assessment and guiding treatment, particularly in people with triglycerides above 200 mg/dL, diabetes, or a very low achieved LDL-C where residual particle-related risk may remain.
So no, everybody doesn’t necessarily need ApoB checked every three months. But in the right patient, it can reveal something LDL-C alone doesn’t.
2. Lp(a): The Cholesterol Test You May Need Only Once
If you remember only one test from this article, remember lipoprotein(a), abbreviated Lp(a).
Lp(a) is an LDL-like particle with an additional protein called apolipoprotein(a) attached to it. High levels are associated with increased risk of atherosclerotic cardiovascular disease and calcific aortic valve disease.
Here’s what makes Lp(a) particularly interesting: your level is largely determined by genetics.
You can eat kale until you turn green and probably won’t substantially change a genetically high Lp(a).
That’s not an argument against a healthy lifestyle. Quite the opposite. If you’ve inherited an additional cardiovascular risk factor you can’t easily modify, controlling the ones you can modify becomes even more important.
The 2026 guideline recommends that every adult have Lp(a) measured at least once. A level of 125 nmol/L (50 mg/dL) or higher is considered a risk-enhancing factor; progressively higher concentrations confer progressively greater risk.
Notice those two different units, too: mg/dL and nmol/L. They are not reliably interchangeable with a single conversion factor because Lp(a) particle size varies between individuals.
That’s a detail worth knowing before you start comparing your result with your sister’s laboratory report.
3. Triglycerides and HDL: Look at the Metabolic Picture
I don’t want you obsessing over ratios and ignoring the actual numbers, but triglycerides and HDL can provide useful metabolic clues.
High triglycerides frequently travel with insulin resistance, abdominal obesity, fatty liver and type 2 diabetes.
Someone might have:
LDL-C: 112
Triglycerides: 260
HDL-C: 36
I wouldn’t look at that LDL of 112 in isolation and declare victory.
Elevated triglycerides can be associated with an increased number of triglyceride-rich remnant particles and ApoB-containing particles. This is one reason ApoB can become especially informative when triglycerides are elevated.
And while higher HDL-C is epidemiologically associated with lower cardiovascular risk, HDL is not a magic shield. Having a high HDL does not cancel out smoking, hypertension, diabetes, elevated ApoB or high Lp(a).
The 2026 guideline makes that point indirectly but importantly: LDL-C and non-HDL-C treatment goals are again part of cardiovascular management.
Non-HDL-C is wonderfully simple:
Total cholesterol minus HDL-C.
It captures cholesterol carried by the major atherogenic particles rather than focusing on LDL alone.
4. hs-CRP: Is Inflammation Adding to the Risk?
High-sensitivity C-reactive protein, or hs-CRP, is a blood marker of systemic inflammation.
Notice I said inflammation, not “inflammation in your coronary arteries.”
That’s an important distinction.
An elevated hs-CRP does not tell you that a coronary artery is inflamed or clogged. CRP can rise because of infection, inflammatory disease, injury and many other circumstances.
But when someone is otherwise clinically stable, hs-CRP can provide additional cardiovascular risk information. The 2026 guideline includes elevated hs-CRP among the markers that may refine ASCVD risk.
Timing matters. If you’re sitting in the laboratory coughing, feverish and fighting influenza, that is probably not the moment to use your hs-CRP to characterize your baseline cardiovascular inflammation.
Context, context, context. 
5. A1C, Glucose—and Sometimes Insulin
You cannot have an intelligent conversation about cardiovascular risk without talking about blood sugar.
Diabetes is a major cardiovascular risk factor. But metabolic dysfunction begins long before many people meet the diagnostic threshold for diabetes.
Hemoglobin A1C estimates average glycemic exposure over approximately the previous two to three months. Fasting glucose provides another piece of information.
And sometimes fasting insulin can provide additional metabolic context, although it is not currently a standardized ASCVD risk marker or a routine screening recommendation in major cardiology guidelines.
I want to be precise about that.
I find insulin resistance biologically fascinating, but we shouldn’t elevate every interesting laboratory test to guideline status.
The bigger message is that cholesterol metabolism and glucose metabolism don’t live on separate planets.
Insulin resistance often travels with high triglycerides, lower HDL-C, hypertension, visceral fat and an increased burden of atherogenic particles.
Your cardiologist may call this cardiometabolic risk. Your body just calls it Tuesday. 
6. CAC: The Test That Actually Looks for Coronary Calcium
Now we leave the blood tube entirely.
A coronary artery calcium scan, or CAC, is a noncontrast CT scan that detects calcified plaque in the coronary arteries.
That’s fundamentally different from predicting risk based solely on biomarkers.
You’re looking for evidence that coronary atherosclerosis has actually developed.
The 2026 guideline expanded the use of CAC scoring for refining risk. In general, it can be particularly useful when a person and clinician are uncertain about whether lipid-lowering medication should be started or how aggressively risk should be treated.
Current guidance says CAC can be considered in men age 40 and older and women age 45 and older when it will help clarify cardiovascular risk and treatment decisions.
A CAC score of zero can be reassuring in appropriately selected people, but it isn’t an invisibility cloak. It doesn’t detect all noncalcified plaque, and it doesn’t erase strong risk factors such as familial hypercholesterolemia or certain high-risk medical conditions.
At the other end of the spectrum, substantial coronary calcium tells you something important: atherosclerosis is already present.
That’s a very different conversation from arguing about whether an LDL of 128 is “a little high.”
7. Thyroid Testing: Because Sometimes Cholesterol Is the Messenger
Here’s the pharmacist in me coming out.
If someone’s cholesterol unexpectedly climbs, especially without an obvious explanation, I want to know what else is happening physiologically.
Hypothyroidism can raise LDL cholesterol and sometimes triglycerides. Thyroid hormone influences LDL-receptor activity and lipid metabolism. When thyroid function slows, clearance of LDL particles can decrease.
That’s why a TSH, often followed by free T4 when appropriate, may belong in the evaluation of unexplained dyslipidemia. And thyroid disease isn’t the only secondary cause worth considering. Kidney disease, liver disease, diabetes, alcohol intake and certain medications can alter lipid levels too.
I’ve spent my career teaching people to ask why a laboratory value changed rather than immediately chasing the number.
Sometimes the cholesterol is the problem, but usually it’s the clue. Chasing cholesterol down is the equivalent of trying to put out a fire in the house by blowing the smoke out with a fan.
What Happened to “Normal” Cholesterol—and Do You Automatically Need a Statin?
If you’ve been getting cholesterol tests for 30 or 40 years, you may have noticed something peculiar: numbers that once barely raised an eyebrow can now trigger a conversation about medication.
I hear some version of this all the time: “My cholesterol isn’t that different from what it was 20 years ago. Why does everyone suddenly want me on a statin?”
There’s some truth buried in that frustration, but the history is more nuanced.
Cholesterol guidelines have evolved dramatically as cardiovascular trials accumulated. We’ve moved from relatively simple cholesterol cutoffs, to LDL targets, then toward treating according to a person’s overall cardiovascular risk, and now we’re combining those ideas.
The new 2026 ACC/AHA dyslipidemia guideline actually brings LDL-C treatment goals back. For primary prevention, the goal may be below 100 mg/dL in someone at borderline or intermediate risk and below 70 mg/dL in someone at high risk. For people who already have atherosclerotic cardiovascular disease and are at very high risk, the LDL-C goal can be below 55 mg/dL.
Those are strikingly low numbers compared with what many of us grew up seeing on laboratory reports.
But here’s the important part: an LDL of 130 does not automatically mean every person needs a statin.
Today’s decision is supposed to consider the whole human being—age, blood pressure, smoking, diabetes, kidney disease, family history, ApoB, Lp(a), and sometimes a coronary calcium score—rather than prescribing solely because one laboratory value crossed an arbitrary line.
And yes, statins remain first-line drug therapy when medication is warranted because they have extensive evidence showing reductions in heart attacks and strokes.
Regular readers also know I’m hardly president of the statin fan club.
My concern has always been appropriate use. Someone with established coronary disease, a previous heart attack, severe hypercholesterolemia or sufficiently high cardiovascular risk is having a very different risk-benefit conversation than an otherwise healthy person with mildly elevated LDL and no evidence of plaque.
A Pharmacist’s Footnote About Statins: The Drug Mugger Effect
If you and your physician decide that a statin is appropriate, there’s another biochemical detail I think you should know.
Statins inhibit an enzyme called HMG-CoA reductase. That’s how they reduce cholesterol production. But this enzyme sits in the mevalonate pathway, and that biochemical pathway isn’t devoted exclusively to making cholesterol.
It is also involved in the body’s production of coenzyme Q10 (CoQ10).
That’s what I call a Drug Mugger effect: a medication accomplishes something useful while potentially interfering with a nutrient or biochemical pathway along the way.
This isn’t merely theoretical. Meta-analyses of randomized controlled trials have found that statin therapy can significantly reduce circulating CoQ10 concentrations. CoQ10 is involved in mitochondrial energy production, which is one reason researchers have investigated whether reduced CoQ10 might contribute to statin-associated muscle symptoms.
Here’s where I want to be very precise: lower CoQ10 in the blood does not prove that everyone taking a statin needs a CoQ10 supplement, nor has CoQ10 supplementation consistently prevented statin-associated muscle symptoms in clinical trials. The clinical significance remains debated.
But I absolutely think it’s a medication-nutrient interaction worth knowing about and discussing with your healthcare professional—especially if muscle pain, weakness, fatigue or exercise intolerance appears after beginning or increasing a statin. 
And statins aren’t the only medications capable of altering nutrients. That’s the premise behind my work on Drug Muggers: sometimes symptoms blamed on aging, diet or another disease may deserve a closer look at the medications you’re taking and the nutrients or pathways they affect.
If you’d like to investigate your own prescriptions, you can visit DrugMuggers.com and look up a medication to learn about potential nutrient depletions and what may need attention or restoration. Think of it as another question to bring to your pharmacist or physician—not a reason to stop a prescribed medication on your own.
The goal isn’t to be anti-drug.
It’s to be pro-informed patient. Speaking of informed, there’s a new category of cholesterol-lowering drugs available today. They’re in the category called PCSK9 drugs and if you can’t remember that, just think of them as “pesky” drugs, lol. These are sold by brand names like Repatha or Praluent. I wrote an article about these pesky drugs – READ HERE.
Don’t Turn This Into a Shopping List of Laboratory Tests
Start with the basics: a standard lipid panel, blood pressure, medical and family history, smoking status, diabetes status, kidney health and overall cardiovascular risk.
Then ask whether additional information would actually change what you do.
For most people, Lp(a) once in a lifetime now has strong guideline support. ApoB is particularly useful in selected situations, including diabetes, metabolic syndrome and elevated triglycerides. hs-CRP may refine risk in some people. CAC can be extremely helpful when the treatment decision remains uncertain.
And don’t forget the boring things because they’re still the powerful things: don’t smoke, move your body, control blood pressure, manage diabetes, sleep adequately, maintain a healthy weight and eat in a way you can sustain.
Supplements don’t get to replace those things.
Neither does a beautiful HDL number.
The Bottom Line
If I could change one thing about how people think about cholesterol, it would be this:
Stop asking, “Is my cholesterol good or bad?”
Ask instead, “What does my entire cardiovascular risk picture look like?”
Your LDL-C matters… like A LOT!
But so can the number of ApoB-containing particles, inherited Lp(a), triglycerides, metabolic health, inflammation, thyroid function, family history and whether plaque is already visible in your coronary arteries.
Modern cardiology is moving toward that broader picture. The 2026 ACC/AHA dyslipidemia guideline itself reflects that evolution, expanding the conversation beyond a single LDL-C value toward more individualized assessment of atherosclerotic risk.
One number rarely tells the whole story, and when it comes to your heart health, the entire story matters!
Related Articles
Irregular Heartbeat? It Could Be AFib (Atrial Fibrillation)
Statins and Cognitive Decline: Unpacking the Link to Dementia & Depression
What to Take if You Take Statins: Restoring 8 Important Nutrients
Can Vitamin C Replace Statins? 3 Potential Benefits for Cardiovascular Health
How Laxatives and Stool Softeners Steal 6 Electrolytes And Trigger Heart Arrhythmias
Suzy Cohen, RPh, has been a licensed pharmacist for over 30 years, blending conventional medicine with natural approaches to help people feel better and live healthier. She is the founder of Script Essentials, a supplement company known for targeted, custom-formulated products, some with patented innovations.
With a special focus on thyroid health, functional medicine, and drug-induced nutrient depletion (what she calls “drug muggers”), Suzy is the author of several books including Thyroid Healthy, Drug Muggers, and Diabetes Without Drugs. She also writes a nationally syndicated health column and shares practical, easy-to-understand guidance with readers around the world.
